Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer

NK cells for cancer immunotherapy

(2020) Noriko Shimasaki et al.   NATURE REVIEWS DRUG DISCOVERY

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy

(2020) Xianwu Wang et al.   ACS Central Science

Aptamer-T Cell Targeted Therapy for Tumor Treatment Using Sugar Metabolism and Click Chemistry

(2020) Chuan-Gang Liu et al.   ACS Chemical Biology

Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors

(2020) Da Zhang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Cord Blood CAR-NK Cells: Favorable Initial Efficacy and Toxicity but Durability of Clinical Responses Not Yet Clear

(2020) Anastasios Karadimitris   CANCER CELL

Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy

(2020) Senlian Hong et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Aptamer‐Engineered Natural Killer Cells for Cell‐Specific Adaptive Immunotherapy

(2019) Shuanghui Yang et al.   Small

Gene Therapy

(2019) Katherine A. High et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR-NK for tumor immunotherapy: Clinical transformation and future prospects

(2019) Wenxiu Wang et al.   CANCER LETTERS

A Single-Step Chemoenzymatic Reaction for the Construction of Antibody–Cell Conjugates

(2018) Jie Li et al.   ACS Central Science

Tumour heterogeneity and resistance to cancer therapies

(2017) Ibiayi Dagogo-Jack et al.   Nature Reviews Clinical Oncology

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

(2016) Hans Klingemann et al.   Frontiers in Immunology

Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor

(2015) Kurt Schönfeld et al.   MOLECULAR THERAPY

Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications

(2015) Mattias Carlsten et al.   Frontiers in Immunology

Treatment of patients with advanced cancer with the natural killer cell line NK-92

(2013) Torsten Tonn et al.   CYTOTHERAPY

Tumour heterogeneity and cancer cell plasticity

(2013) Corbin E. Meacham et al.   NATURE

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

(2009) Nicola Normanno et al.   Nature Reviews Clinical Oncology

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE